ILLUMINATE Trial: Difference between revisions

	High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
ILLUMINATE Trial On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of ILLUMINATE Trial All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on ILLUMINATE Trial
CDC on ILLUMINATE Trial
ILLUMINATE Trial in the news
Blogs on ILLUMINATE Trial
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for ILLUMINATE Trial

VisualWikitext

Revision as of 11:55, 18 September 2013

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

  Normal  0          false  false  false    EN-US  X-NONE  AR-SA                                                                     Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor.

Dates

Start Date

  Normal  0          false  false  false    EN-US  X-NONE  AR-SA                                                                     August 23, 2004

End Date

  Normal  0          false  false  false    EN-US  X-NONE  AR-SA

· Premature Termination on December 2, 2006. Data collection continued till July 15, 2007.

Methods

Results

Study Outcomes

Conclusion

References

@@ Line 3: / Line 3: @@
 {{CMG}}
-==Overview==
-* Clinical research on [[torcetrapib]] stopped because of increased incidence of cardiovascular events as an adverse effect of the drug.<ref name="pmid17984165">{{cite journal |author=Barter PJ, Caulfield M, Eriksson M, ''et al.'' |title=Effects of torcetrapib in patients at high risk for coronary events |journal=[[The New England Journal of Medicine]] |volume=357 |issue=21 |pages=2109–22 |year=2007 |month=November |pmid=17984165 |doi=10.1056/NEJMoa0706628 |url=}}</ref>
+==Objective==
-* [[Torcetrapib]] side-effects include a significant increase in systolic blood pressure ([[hypertension]]) and a significant reduction in [[serum potassium]] ([[hypokalemia]]) levels.
+   Normal  0          false  false  false    EN-US  X-NONE  AR-SA                                                                     Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor.
+==Dates==
+===Start Date===
+   Normal  0          false  false  false    EN-US  X-NONE  AR-SA                                                                     August 23, 2004
+===End Date===
+   Normal  0          false  false  false    EN-US  X-NONE  AR-SA
+·         Premature Termination on December 2, 2006.  Data collection continued till July 15, 2007.
+==Methods==
+==Results==
+==Study Outcomes==
+==Conclusion==
 ==References==

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL

ILLUMINATE Trial: Difference between revisions

Revision as of 11:55, 18 September 2013

Objective

Dates

Start Date

End Date

Methods

Results

Study Outcomes

Conclusion

References

Navigation menu